

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/774,040
Sheet	2	Filing Date	02/06/2004
	of	First Named Inventor	Justin T. Ernst
	9	Group Art Unit	1616
		Examiner Name	Unknown
		Attorney Docket Number	060621-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>o</sup>
RK	A17	AKIMARU et al., "Formulation and antitumor efficacy of liposomal-caprylated-TNF-Sam <sub>2</sub> ," Cytokines Mol. Ther. 1:197-210, (1995)	
RK	A18	ALBERT, "Reactions of 3,4,6-Trialkylphenols. III. Oxidation Studies," _____ 76:4983-4985 (1954) October	
RK	A19	ALLEN and GATES, "The Behavior of Certain Carbonyl Bridge Compounds with Alkaline Hydrogen Peroxide," Carbonyl Bridge Compounds with Alkaline Hydrogen Peroxide, 64:2439-2442 (1942) October	
RK	A20	ALLEN and GATES, "An Apparently Anomalous Bromination in the Polyphenylindene Series," An Apparently Anomalous Bromination in the Polyphenylindene, 65:419-422 (1943) March	
RK	A21	ALLEN and GATES, "Oxidoketones in the Indene Series," _____, 65:1230-1235 (1943) June	
RK	A22	ALVING, "Liposomes as Carriers of Peptide Antigens: Induction of Antibodies and Cytotoxic T Lymphocytes to Conjugated and Unconjugated Peptides," Immunol. Rev. 145:5-31; (1995)	
RK	A23	BAI, et al., "Nasal Administration of Myelin Basic Protein Prevents Relapsing Experimental Autoimmune Encephalomyelitis in DA Rats by Activating Regulatory Cells Expressing IL-4 and TGF- $\beta$ mRNA," J. Neuroimmunol. 80:65-75; (1997)	
RK	A24	BLAIR et al. "HIV-1 Entry - An Expanding Portal for Drug Discovery," Drug Discovery Today, 5, 183-194 (2000) May	
RK	A25	BODOR, N., "Novel Approaches in Prodrug Design," Drugs of the Future 6:165-182 (1981)	
RK	A26	CHAN and KIM, "HIV Entry and Its Inhibition," Cell, 93, 681-684 (1998) May	
RK	A27	DEBNATH et al., "Structure-Based Identification of Small Molecule Antiviral Compounds Targeted to the gp41 Core Structure of the Human Immunodeficiency Virus Type I," J. Med. Chem. 42:3203-3209 (1999)	

\*no month provided

Examiner Signature	R. Karp	Date Considered	9/27/06
--------------------	---------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for PTO/USPTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>			
(use as many sheets as necessary)		Application Number	10/774,040		
		Filing Date	02/06/2004		
		First Named Inventor	Justin T. Ernst		
		Group Art Unit	1616		
		Examiner Name	Unknown		
Sheet	3	of	9	Attorney Docket Number	060621-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RL	A28	DOMS et al. "HIV-1 Membrane Fusion: Targets of Opportunity," <i>J. Cell Biol.</i> , 151, F9-F13 (2000) <i>October</i>	
RL	A29	ECKERT and KIM, "Mechanisms of Viral Membrane Fusion and Its Inhibition," <i>Annu. Rev. Biochem.</i> , 70; 777-810 (2001)	
RL	A30	EZCURRA et al, "Rearrangements of 4-Alkynyl-, 4-Alkenyl-, and 4-Alkyl-4-Hydroxy-3-Methylenecyclobutenes," <i>J. Org. Chem.</i> , 57:4787-4789 (1992)	
RL	A31	FIX, "Oral Controlled Release Technology for Peptides: Status and Future Prospects," <i>Pharm Res.</i> 13: no. 12,1760-1764; (1996)	
RL	A32	GIACOMELLO, E. et al., "Centrifugal Assay for Fluorescence-Based Cell Adhesion Adapted to the Analysis of Ex Vivo Cells and Capable of Determining Relative Binding Strengths," <i>BioTechniques</i> 26:758 - 766 (1998)	
RL	A33	GURUN, "Studies on the Safety of Glucose and Paraben-Containing Neostigmine for Intrathecal Administration," <i>Anesth Analg.</i> 85:317-323 (1997)	
RL	A34	HAWKINS, D.M. and KASS, G.V., "Automatic Interaction Detection," <i>Topics in Applied Multivariate Analysis</i> ; Hawkins, D. H., Ed.; Cambridge University Press, pp. 269-302 (1982)	
RL	A35	HAWKINS, et al. "Analysis of a Large Structure-Activity Data Set Using Recursive Partitioning," <i>Quant. Struct.-Act. Relat.</i> 16:296-302 (1997)	
RL	A36	HEY and JACKSON, "Migration Reactions in Polycyclic Systems. Part I. The Fries Rearrangement of 4-Benzoyloxydiphenyl," <i>The University, Manchester</i> , 802-806 (1936)	


\* no month provided

Examiner Signature	R. Key	Date Considered	9/27/06
--------------------	--------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1-299 (Rev. 10-2002) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	10/774,040
		<b>Filing Date</b>	02/06/2004
		<b>First Named Inventor</b>	Justin T. Ernst
		<b>Group Art Unit</b>	1616
		<b>Examiner Name</b>	Unknown
		<b>Attorney Docket Number</b>	060621-0703
<b>Sheet</b>	4	<b>of</b>	9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RK	A37	HILL and ADAMS, "Stereochemistry of Phenylquinones. The Preparation and Resolution of 2-(3-Bromo-2,4,6-Trimethylphenyl)-5-Methylbenzo-Quinone-3,6-DI-(Acetic Acid)," Stereochemistry of Phenylquinones, XVIII: 3453-3461 (1931) September	
RK	A38	HUNTLEY et al., "RFI-841, a Potent Respiratory Syncytial Virus Inhibitor," Antimicrobial Agents and Chemotherapy, 46, no. 3, 841-47 (2002) March	
RK	A39	JACOBY, "Biphenyls as Potential Mimetics of Protein x-Helix," Biorganic & Medical Chemistry Letters 12, 12:891-893 (2002)	
RK	A40	JIANG and DEBNATH, "Development of HIV Entry Inhibitors Targeted to the Coiled-Coil Regions of gp41," Biochem. Biophys. Res. Commun., 269, 641-646; (2000)	
RK	A41	JIANG et al., "Peptide and Non-Peptide HIV Fusion Inhibitors," Curr. Pharm. Design, 8, 125-133, (2002)	
ll	A42	KATI et al., "In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication," Antimicrobial Agents and Chemotherapy, 46:1014-1021 (2002) April	
RK	A43	KOGEN et al., "Rational Design and Synthesis of Small Molecule, Non-Oligosaccharide Selectin Inhibitors: (α-D-Mannopyranosyloxy) Biphenyl-Substituted Carboxylic Acids," J. Med. Chem., 38:4976-4984 (1995)	

\* no month provided

<b>Examiner Signature</b>	R. Kay	<b>Date Considered</b>	9/27/06
---------------------------	--------	------------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/774,040
Filing Date	02/06/2004
First Named Inventor	Justin T. Ernst
Group Art Unit	1616
Examiner Name	Unknown
Attorney Docket Number	060621-0703

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RK	A44	KUROSAWA et al., "The Reactions of 2-Hydroxybenzophenones with Lead Tetraacetate and Manganic Acetate," Bulletin of the Chemical Society of Japan, 46:1498-1501 (1973)	
RK	A45	KUTZKI, et al., "Development of a Potent Bcl-x <sub>L</sub> Antagonist Based on α-Helix Mimicry," J. Am. Chem., 124:11838-11839 (2002) September	
RK	A46	LABRANCHE et al. "HIV Fusion and Its Inhibition," <i>Antiviral Res.</i> , 50: 95-115; (2001)	
RK	A47	LESUISSE et al., "Biphenyls as Surrogates of the Steroidal Backbone. Part 1: Synthesis and Estrogen Receptor Affinity of an Original Series of Polysubstituted Biphenyls," Biorganic and Medicinal Chemistry Letters, 11:1709-1712 (2001).	
RK	A48	LIU et al., "Synthesis and Characterization of Polyquinolines for Light-Emitting Diodes," J. Mater. Chem., 9:2201-2204 (1999)	
RK	A49	LIU et al., "Synthesis and Characterization of Quinoline-Based Copolymers for Light Emitting Diodes," J. Mater. Chem., 11:1800-1804 (2001)	
RK	A50	LIU et al., "Synthesis and Characterization of a Novel Bipolar Polymer for Light-Emitting Diodes," Chem. Commun., 2747-2748 (1998)	


\* no month provided

Examiner Signature	R. Key	Date Considered	9/27/06
--------------------	--------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 449B/PTO-101		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	10/774,040		
		Filing Date	02/06/2004		
		First Named Inventor	Justin T. Ernst		
		Group Art Unit	1616		
		Examiner Name	Unknown		
Sheet	6	of	9	Attorney Docket Number	060621-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PK	A51	MARUSIC and TONEGAWA, "Tolerance Induction and Autoimmune Encephalomyelitis Amelioration After Administration of Myelin Basic Protein-Derived Peptide," J. Exp. Med. 186, no. 4:507-515 (1997) August	
PK	A52	MIGLIORESE et al., "Skipped Diynes. V. Secondary Diethynylcarbinols, a Base-Catalyzed Ynol to Enol Rearrangement, and Ultraviolet Spectra and Conjugation," Journ. of Organic Chemistry, 39:, no. 6:739-747 (1974) March	
PK	A53	NAKAMURA et al., "Design, Synthesis, and Evaluation of the Transition-State Inhibitors of Coelenterazine Bioluminescence: Probing the Chiral Environment of Active Site," J. Am. Chem. Soc. 123:1523-1524 (2001)	
PK	A54	NOTARI, R.E., "Theory and Practice of Prodrug Kinetics," Methods in Enzymology 112:309-323 (1985)	
PK	A55	ORNER et al., "Toward Proteomimetics: Terphenyl Derivatives as Structural and Functional Mimics of Extended Regions of an $\alpha$ -Helix," J. Am. Chem., 123:5382-5383 (2001)	
PK	A56	PAKKAL et al., "Study of the Double Fries Rearrangement. II. Rearrangement of Diesters of 4,4'-Biphenol," 25:282-283 (1960) February 1960.	
PK	A57	PARKER G.J. et al., "Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/Phosphatase Assays," Journal of Biomolecular Screening 5(2):77-88 (2000)	

\* no month provided


Examiner Signature	R. Kay	Date Considered	9/27/06
--------------------	--------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PAB-PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/774,040
		Filing Date	02/06/2004
		First Named Inventor	Justin T. Ernst
		Group Art Unit	1616
		Examiner Name	Unknown
Sheet	7	of	9
		Attorney Docket Number	060621-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RK	A58	PUTNEY, et al., "Improving Protein Therapeutics with Sustained-Release Formulations," Nat. Biotechnol. 16:153-157. (1998) February	
RK	A59	RAJCA et al., "Near-Degeneracy Between the Low- and High-Spin States in an Alternant Hydrocarbon Diradical: Topology and Geometry," J. Org. Chem., 58:5650-5652 (1993)	
RK	A60	RUSINKO, et al., "Analysis of a Large Structure/Biological Activity Data Set Using Recursive Partitioning," J. Chem. Inf. Comput. Science 39:1017-1026 (1999) October	
RK	A61	SAMANEN, et al., "Chemical Approaches to Improve the Oral Bioavailability of Peptidergic Molecules," J. Pharm. Pharmacol, 48:119-135, (1996)	
RK	A62	SATO and OKI, "Estrogenic Biphenyls. VI 2- and 6'-Alkyl Derivatives of 3'-Ethyl-4-Methoxy-Biphenyl-4'-Carboxylic Acid," Estrogenic Biphenyls, 32, no. 12:1289-1291 (1959) December	
RK	A63	SAWYER, "Recent Advances in Diaryl Ether Synthesis" Tetrahedron, 56: 5045-5065, (2000)	
RK	A64	SCHOLL et al., "Eine Neue Synthese Des 4.4'-Dimethyl-Pyranthrons," Eingegangen am, 7, 512-518 (1910) February	


\*no month provided

Examiner Signature	R. Kerp	Date Considered	9/27/06
--------------------	---------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/774,040
Sheet	8	Filing Date	02/06/2004
	of	First Named Inventor	Justin T. Ernst
	9	Group Art Unit	1616
		Examiner Name	Unknown
		Attorney Docket Number	060621-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PK	A65	SCHOLL and SEER, "5-p-Tolyl-2-methylbenzophenon-2'-Carbonsäure Odor 4,4'-Di-Methyl-1,1'-Diphenyl-3-Phthaloylsäure (Formel XI)," Verhalten Einiger Anthrachinonderivate, 543-548, 1911.	
PK	A66	SUGITA and TAMURA, "Stereochemical Studies in Friedel-Crafts Reactions. II. The Reactions of 4-Substituted Cyclohexenes with Benzene," Bulletin of the Chemical Society of Japan, 44:3388-3391 (1971)	
PK	A67	SUNTRES and SHEK, "Incorporation of $\alpha$ -Tocopherol in Liposomes Promotes the Retention of Liposome-Encapsulated Glutathione in the Rat Lung," J. Pharm. Pharmacol. 46:23-28; (1994)	
PK	A68	SUZUKI, "Recent Advances in the Cross-Coupling Reactions of Organoboron Derivatives with Organic Electrophiles," J. Organomet. Chem., 576: 147-168 (1999)	
PK	A69	SZOKA, "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)," Ann. Rev. Biophys. Bioeng, 9:467-508; (1980)	
PK	A70	TAVERNOR et al., "AlCl <sub>3</sub> -DMF Complex as Catalyst in the Friedel-Craft Reaction. The Reactivity of Anhydrides and Chlorides of Dicarboxylic Acids," Bull. Soc. Chim. Belg., 106:791-801 (1997)	
PK	A71	VUTLA, et al., "Transdermal Iontophoretic Delivery of Enkephalin Formulated in Liposomes," J. Pharm. Sci. 85:5-8 (1996) January	

\* no month provided


Examiner Signature	R. Karp	Date Considered	9/27/06
--------------------	---------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for PTO/SB/08/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/774,040
		Filing Date	02/06/2004
		First Named Inventor	Justin T. Ernst
		Group Art Unit	1616
		Examiner Name	Unknown
Sheet	9	of	9
		Attorney Docket Number	060621-0703

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
PK	A72	WARREN, et al., "Tolerance Induction to Myelin Basic Protein by Intravenous Synthetic Peptides Containing Epitope P <sub>85</sub> VVHFFKNIVTP <sub>98</sub> in Chronic Progressive Multiple Sclerosis," Journ. of Neurol. Sci. 152:31-38; (1997)	
PK	A73	WILD et al., "Peptides Corresponding to a Predictive $\alpha$ -Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection," Proc. Natl. Acad. Sci. USA, 91, 9770-9774 (1994) October	
PK	A74	WILSON et al., "Epitopes Involved in Antibody-Mediated Protection from Ebola Virus," Science, 287:1664-1666 (2000) March	
PK	A75	WITIAK et al., "Comparative Antilipidemic Effects of Various Ethyl 5-Substituted Benzofuran-, 2,3-Dihydrobenzofuran-, and 3(2H)-Benzofuranone-2-Carboxylate Analogs of Clofibrate in a Triton Hyperlipidemic Rat Model," LIPIDS, 11, no. 5:384-391 (1976)	
PK	A76	WOODLE, et al., "Prolonged Systemic Delivery of Peptide Drugs by Long-Circulating Liposomes: Illustration with Vasopressin in the Brattleboro Rat," Pharm. Res. 9:260-265 (1992)	
PK	A77	WU et al., "Chemical Studies on the Chiral Indanone Derivatives as the Inhibitor of Renilla Luciferase," Tetrahedron, 57:9575-9583 (2001)	
PK	A78	ZALIPSKY, et al., "Peptide Attachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-Circulating Form of Laminin Pentapeptide, YIGSR," Bioconjug. Chem. 6:705-708 (1995)	

\* no month provided

Examiner Signature	R. Kopp	Date Considered	9/27/06
--------------------	---------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.